Screener
Allogene Therapeutics ALLO Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $395,958 | $415,905 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,933 | $4,270 |
| Accrued and other current liabilities | 23,397 | 28,244 |
| Total current liabilities | 28,330 | 32,514 |
| Lease liability, noncurrent | 72,633 | 75,045 |
| Other long-term liabilities | 16,120 | 15,804 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's accounts payable?
- Allogene Therapeutics (ALLO) reported accounts payable of $4.93M in Q1 2026.
- How has Allogene Therapeutics's accounts payable changed year-over-year?
- Allogene Therapeutics's accounts payable decreased by 2.5% year-over-year, from $5.06M to $4.93M.
- What is the long-term trend for Allogene Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Allogene Therapeutics's accounts payable has grown at a -16.3% compound annual growth rate (CAGR), from $10.39M to $4.27M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Allogene Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude